Caris Life Sciences stock
CAINASDAQCaris Life Sciences, Inc., HealthcareISIN US1421521071
58Score 58 out of 100, Neutral
Price and trend
61 / 100
Price history
−3.3% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 29).
The price is 34% below its 52-week high. Largest decline in 1 year: 63% (August 2025 to May 2026).
Chart figures for advanced users
- SMA 50$29.43
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$21.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)29
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.55
- The lowest closing price of the last twelve months.
- Resistance$36.14
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Caris Life Sciences, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $6.87B, is number 57 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $812.03M (up 97% year on year) and a loss of $537.96M.
- For fiscal 2026, analysts expect on average revenue of $1.03B (up 26.8%) and adjusted earnings per share of $0.12.
Show more
- MEQIRI Score 58 out of 100 (Neutral): rank 300 of 714 in Healthcare, median 53.
- Our model puts fair value at $12.09, with the price 103% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $767.38M, financial debt $462.76M.
Weaknesses
- Above fair valuePrice 103% above the fair value of $12.09.Valuation 22
- Volatile share priceVolatility 69% a year over the last 12 months.Stability 47
- DilutionShare count up 11% since 2022.Capital allocation 64
Its standout strength is profitability, while stability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 57 to 58.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $8.06 and expensive above $24.18 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $17.25 (cash-flow model) and $6.93 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $11.28, at 8.5% it would be $13.20.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 61.5% on the twelve months before. Revenue has grown strongly since 2005, at around 15% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 66%, operating 6%, net −66%. Last 12 months: net 9%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 4 Nov 2026EPS reported $0.05 (expected $0.03)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.12+1.0%
- Revenue
- $1.03B0.0%
- Earnings per share
- $0.35+0.8%
- Revenue
- $1.23B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +24.2%2026 revenue outlook raised to $1.03 billion to $1.04 billion from $1.0 billion to $1.02 billion (27% to 28% growth).
“We now expect total revenue of $1.03 billion to $1.04 billion, representing 27% to 28% growth, up from the prior range of $1 billion to $1.02 billion, driven by that continued molecular profiling strength.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $990,080 in total. 3 insiders sold, $27.2M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Caris Life Sciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Rhythm PharmaceuticalsRYTM $7.78B46
- ImmunovantIMVT $7.64B45
- Bachem HoldingBANB.SW $7.3B58
- ImmunityBioIBRX $7.1B38
- Arrowhead PharmaceuticalsARWR $6.97B32
- Kodiak SciencesKOD $6.87B43
- Samsung Epis Holdings0126Z0.KS $6.58B41
- CG OncologyCGON $6.49B41
ETFs that hold Caris Life Sciences
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 2.85% | 0.50% | €127.06M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.48% | 0.35% | €1.21B |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.35% | 0.40% | €1.49B |
Show 5 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.